Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Anticancer Res. 2018 Jun;38(6):3299–3307. doi: 10.21873/anticanres.12595

Figure 3.

Figure 3

Expression of nuclear factor kappa-B (NF-κB) subunits p65 and p50 (A) and mediators of the NF-κB pathway, IκB kinase alpha (IKK-α) and IKK-β, (B) in hapalindole H (Hap H)-treated PC-3 cells. Rocaglamide was used as a positive control.